DEBRA SCHEXNAYDER: Open Payments
NPI 1073557872 · HARVEY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,173 in 56 payments from 13 companies in 2025. Trend: 2023 $1,120 · 2024 $1,291 · 2025 $1,173
Food & beverage: $1,173
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $263 |
| Lilly USA, LLC | 12 | $250 |
| AstraZeneca Pharmaceuticals LP | 9 | $196 |
| COLOPLAST CORP | 1 | $111 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $86 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $67 |
| GlaxoSmithKline, LLC. | 3 | $54 |
| PFIZER INC. | 3 | $50 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $20 |
Products named: MOUNJARO, BREZTRI, UBRELVY, Altis, ZEPBOUND, CREON, JARDIANCE, AIRSUPRA.
Industry payments across LA — which companies pay providers there.
